Daré Bioscience Enters Up To $15M Common Stock Purchase Agreement With Lincoln Park Capital Fund
Portfolio Pulse from Benzinga Newsdesk
Daré Bioscience has entered into a common stock purchase agreement with Lincoln Park Capital Fund, allowing for the sale of up to $15 million in common stock. This agreement provides Daré with potential capital to support its operations and growth initiatives.
October 21, 2024 | 12:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Daré Bioscience has signed a common stock purchase agreement with Lincoln Park Capital Fund, enabling the sale of up to $15 million in common stock. This agreement could provide Daré with necessary capital for its operations and growth.
The agreement with Lincoln Park Capital Fund allows Daré Bioscience to raise up to $15 million through the sale of common stock. This influx of capital can support the company's operations and growth initiatives, which is likely to have a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100